OMEROS CORP Payments to Acquire Marketable Securities
OMEROS CORP (OMER) reported Payments to Acquire Marketable Securities of $11.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-12
- OMEROS CORP payments to acquire marketable securities for the quarter ending 2026-06-30 was $10.15M, a 2503.85% increase year-over-year.
- OMEROS CORP payments to acquire marketable securities for the quarter ending 2026-03-31 was $1.32M, a 83.29% increase year-over-year.
- OMEROS CORP payments to acquire marketable securities for the quarter ending 2025-12-31 was $166.85M, a 154.48% increase year-over-year.
- OMEROS CORP payments to acquire marketable securities for the quarter ending 2025-09-30 was $17.35M, a 94.13% decline year-over-year.
- OMEROS CORP payments to acquire marketable securities for fiscal 2025 was $185.31M, a 81.23% decline from fiscal 2024.
- OMEROS CORP payments to acquire marketable securities for fiscal 2024 was $987.38M, a 3.06% decline from fiscal 2023.
- OMEROS CORP payments to acquire marketable securities for fiscal 2023 was $1.02B, a 137.41% increase from fiscal 2022.
- OMEROS CORP payments to acquire marketable securities for fiscal 2022 was $429.05M, a 1240.51% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $11.47M 10-Q · filed 2026-08-12 | $178.32M derived: sum of 3 quarters · filed 2026-08-12 | $195.68M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.32M 10-Q · filed 2026-05-13 | $168.17M derived: sum of 2 quarters · filed 2026-05-13 | $185.52M derived: sum of 3 quarters · filed 2026-05-13 | $185.91M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $166.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $184.20M derived: sum of 2 quarters · filed 2026-03-31 | $184.59M derived: sum of 3 quarters · filed 2026-08-12 | $185.31M 10-K · filed 2026-03-31 |
| 2025-09-30 | $17.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $17.74M derived: sum of 2 quarters · filed 2026-08-12 | $18.46M 10-Q · filed 2025-11-13 | $84.02M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $390.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.11M 10-Q · filed 2026-08-12 | $66.67M derived: sum of 3 quarters · filed 2026-08-12 | $362.44M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $718.00K 10-Q · filed 2026-05-13 | $66.28M derived: sum of 2 quarters · filed 2026-05-13 | $362.05M derived: sum of 3 quarters · filed 2026-05-13 | $500.55M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $65.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $361.33M derived: sum of 2 quarters · filed 2026-03-31 | $499.83M derived: sum of 3 quarters · filed 2026-03-31 | $987.38M 10-K · filed 2026-03-31 |
| 2024-09-30 | $295.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $434.26M derived: sum of 2 quarters · filed 2025-11-13 | $921.82M 10-Q · filed 2025-11-13 | $1.10B derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | $138.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $626.05M 10-Q · filed 2025-08-14 | $805.06M derived: sum of 3 quarters · filed 2026-03-31 | $981.91M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | $487.55M 10-Q · filed 2025-05-15 | $666.56M derived: sum of 2 quarters · filed 2026-03-31 | $843.42M derived: sum of 3 quarters · filed 2026-03-31 | $982.22M derived: sum of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | $179.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $355.86M derived: sum of 2 quarters · filed 2026-03-31 | $494.66M derived: sum of 3 quarters · filed 2026-03-31 | $1.02B 10-K · filed 2026-03-31 |
| 2023-09-30 | $176.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $315.65M derived: sum of 2 quarters · filed 2024-11-13 | $839.60M 10-Q · filed 2024-11-13 | $1.17B derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $138.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $662.74M 10-Q · filed 2024-08-07 | $988.21M derived: sum of 3 quarters · filed 2025-03-31 | $988.61M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $523.94M 10-Q · filed 2024-05-15 | $849.41M derived: sum of 2 quarters · filed 2025-03-31 | $849.82M derived: sum of 3 quarters · filed 2025-03-31 | $869.97M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $325.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $325.88M derived: sum of 2 quarters · filed 2025-03-31 | $346.03M derived: sum of 3 quarters · filed 2025-03-31 | $429.05M 10-K · filed 2025-03-31 |
| 2022-09-30 | $404.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $20.56M derived: sum of 2 quarters · filed 2023-11-09 | $103.57M 10-Q · filed 2023-11-09 | $135.57M derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-06-30 | $20.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $103.17M 10-Q · filed 2023-08-09 | $135.17M derived: sum of 3 quarters · filed 2024-04-01 | $135.17M derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-03-31 | $83.01M 10-Q · filed 2023-05-09 | $115.01M derived: sum of 2 quarters · filed 2024-04-01 | $115.02M derived: sum of 3 quarters · filed 2024-04-01 | $115.02M derived: sum of 4 quarters · filed 2024-04-01 |
| 2021-12-31 | $32.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $32.00M derived: sum of 2 quarters · filed 2024-04-01 | $32.00M derived: sum of 3 quarters · filed 2024-04-01 | $32.01M 10-K · filed 2024-04-01 |
| 2021-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.00K derived: sum of 2 quarters · filed 2022-11-09 | $5.00K 10-Q · filed 2022-11-09 | $9.00K derived: sum of 4 quarters · filed 2023-03-13 |
| 2021-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.00K 10-Q · filed 2022-08-09 | $8.00K derived: sum of 3 quarters · filed 2023-03-13 | $130.01M derived: sum of 4 quarters · filed 2023-03-13 |
| 2021-03-31 | $3.00K 10-Q · filed 2022-05-10 | $7.00K derived: sum of 2 quarters · filed 2023-03-13 | $130.01M derived: sum of 3 quarters · filed 2023-03-13 | $130.02M derived: sum of 4 quarters · filed 2023-03-13 |
| 2020-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $130.01M derived: sum of 2 quarters · filed 2023-03-13 | $130.02M derived: sum of 3 quarters · filed 2023-03-13 | $133.19M 10-K · filed 2023-03-13 |
| 2020-09-30 | $130.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $130.01M derived: sum of 2 quarters · filed 2021-11-09 | $133.19M 10-Q · filed 2021-11-09 | $190.81M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.19M 10-Q · filed 2021-08-09 | $60.81M derived: sum of 3 quarters · filed 2022-03-01 | $60.93M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $3.18M 10-Q · filed 2021-05-10 | $60.80M derived: sum of 2 quarters · filed 2022-03-01 | $60.92M derived: sum of 3 quarters · filed 2022-03-01 | $61.11M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $57.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $57.74M derived: sum of 2 quarters · filed 2022-03-01 | $57.94M derived: sum of 3 quarters · filed 2022-03-01 | $58.22M 10-K · filed 2022-03-01 |
| 2019-09-30 | $122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $313.00K derived: sum of 2 quarters · filed 2020-11-09 | $594.00K 10-Q · filed 2020-11-09 | $23.86M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $191.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $472.00K 10-Q · filed 2020-08-10 | $23.74M derived: sum of 3 quarters · filed 2021-03-01 | $24.09M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $281.00K 10-Q · filed 2020-05-11 | $23.55M derived: sum of 2 quarters · filed 2021-03-01 | $23.90M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $23.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $23.62M derived: sum of 2 quarters · filed 2021-03-01 | $68.78M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $348.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $45.51M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $45.17M 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $65.33M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |